Risk Factors and Real-World Short-Term Outcomes of a Failed Trial of Void After Rezum Therapy in a Multiethnic Population

Efficacy and safety of the Rezum system for the treatment of catheter‐dependent urinary retention: Three‐year real‐world outcomes in a multimorbid, multiethnic population

“…More importantly, all cases of UTI and the majority of cases of dysuria in our study occurred in the patients who failed their initial TOV. In a previous study, we identified a high baseline PVR, particular >200 mL, as the only independent risk factor for a failed TOV 19 . However, for the present study, we were not able to identify factors associated with TOV failure regarding baseline and procedural characteristics, which may be due to the small sample size in two cohorts (failed initial TOV, 14 patients; passed initial TOV, 13 patients).…”

“…In a previous study, we identified a high baseline PVR, particular >200 mL, as the only independent risk factor for a failed TOV. 19 However, for the present study, we were not able to identify factors associated with TOV failure regarding baseline and procedural characteristics, which may be due to the small sample size in two cohorts (failed initial TOV, 14 patients; passed initial TOV, 13 patients). Until a larger study is conducted that evaluates risk factors of a failed TOV following Rezum in patients with urinary retention, we recommend leaving in postoperative urinary catheters for an extended period following treatment, preferably for at least 2 weeks as this was the median time to catheter independence observed in our study.…”

Long-Term Water Vapor Thermal Therapy Outcomes Across a Broad Range of Prostate Volumes

“…A higher proportion of patients in the > 80 cc cohort had a past medical history of urinary retention (25%) compared to the < 30 cc (5.7%, P ¼ .04) and 30 to 80 cc (4.1%, P < .001) cohorts. The < 30 cc cohort had significantly higher baseline IPSS (median 21 [IQR 15 -28]) and QoL (5 [4-6]) compared to the 30 to 80 cc (IPSS 17 [10][11][12][13][14][15][16][17][18][19][20][21][22][23] Regarding IIEF measures, at 48 months there was slight worsening of orgasmic function in the < 30 cc cohort (À50%, P ¼ .04) but an improvement in the 30 to 80 cc cohort (25%, P ¼ .004). At 48 months, erectile function improved in the 30 to 80 cc cohort (15.4%, P ¼ .006) with insignificant changes in the < 30 cc and > 80 cc cohorts.…”

“…16 While current literature is favorable, long-term real-world data remain limited. [17][18][19][20][21] Additionally, WVTT is indicated only for men with a PV between 30 cc and 80 cc, as studied in its randomized control trial. 12,22 This excludes men with larger PVs (who may bear greater morbidity) and with smaller PVs (who may also benefit from reduction of excess tissue).…”